Novel Treatments for Chronic Viral Infections
ContraVir seeks to develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic viral infections, with an initial focus on herpes zoster, or shingles, and hepatitis B.
A Shingles Treatment with Best in Class Potential
Our lead candidate is FV-100, a potent oral antiviral being developed for the treatment of herpes zoster, commonly known as shingles. FV-100 is well-tolerated and has been shown to reduce PHN pain in Phase 2 trials.
ContraVir is developing a portfolio of novel compounds against hepatitis B, including CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor. ContraVir is also developing FV-100, now in Phase 3 trials, for the treatment of herpes zoster, or shingles, and the pain associated with shingles.
ContraVir is focused on curing hepatitis B through combination of best-in-class, direct- and indirect-acting antiviral compounds. Its two current assets have complementary mechanisms of action against hepatitis B virus (HBV): CMX157 is a highly potent prodrug of tenofovir, marketed by Gilead as Viread®; CRV431 is positioned to be the leading next-generation cyclophilin inhibitor antiviral designed to selectively inhibit HBV.
- Potential for lower dosing: 97-fold more potent than tenofovir in vitro
- Potential to improve safety (reduced plasma exposure to tenofovir) compared to Viread®
- Potential to improve efficacy (increased active tenofovir in target liver cells) compared to Viread®
- Best-in-class potency and optimized selective index for HBV
- Interrupts HBV life cycle at multiple points
- Reduces liver injury through unique anti-fibrotic mechanism
ContraVir is developing FV-100 as a fast-acting, low-dose, once-daily, oral antiviral therapy for the treatment of herpes zoster, or shingles, an infection caused by the reactivation of the varicella zoster (chicken pox) virus. In addition to its potent antiviral activity, FV-100 has demonstrated an ability to reduce shingles-associated pain, known as post-herpetic neuralgia, or PHN.
- Conducting a Phase 3 clinical study
- Well-tolerated with demonstrated reduction in PHN in Phase 2 trials
- Potential for more convenient dosing; no dose adjustment required for patients with renal insufficiency
- Strong IP position